Life sciences

Licentieaanbod:

Highly selective and high-affinity autophagy inhibitors for development in oncology


The University of Antwerp has discovered the most potent and selective small molecule autophagy inhibitors reported to date. Compounds target autophagy in a highly specific manner, via inhibition of the cysteine protease Atg4B. Target audience for the technology: pharma/biotech partners that are looking for a development candidate in oncology. More info

 

Lead compounds for dry eye disease and validated dry eye disease rat model


The University of Antwerp has developed a new lead compound and a validated rat model for dry eye disease (DED). Pharmaceutical companies looking for a preclinical candidate for further development in DED related disease can benefit from this established expertise.  More info 

 

 

Orally bioavailable inhibitors of fibroblast activation protein (FAP) with development potential in fibrosis, oncology and pathologic tissue remodeling


The University of Antwerp has discovered the most potent and selective small molecule FAP inhibitors reported to date. Compounds have low nanomolar affinities, are orally bioavailable and induce stable, long-term in vivo inhibition. Target audience for the technology: pharma/biotech partners that are looking for a development candidate in oncology and diseases characterized by fibrosis and tissue remodeling. More info

 

Serine protease inhibitors to treat visceral pain


The University of Antwerp has developed an in vivo proof of concept with serine protease inhibitors in a validated gastrointestinal IBS model for visceral pain. Pharmaceutical companies looking to further test these preclinical candidates for further development in visceral pain-related pathologies can benefit from this established expertise. More info

 

Smart lab monitoring, powered by artificial intelligence


The University of Antwerp has developed advanced artificial intelligence and machine learning techniques to automatically measure and analyze laboratory performance metrics. This technology enables systematic, unsupervised quality control in biomedical laboratories. More generally it allows the integration of complex process data from a wide variety of connected input sources. More info

 

Contact

Vincent Pruniau
Valorisatiemanager Life Sciences
Campus Middelheim - Gebouw A
M.A.108
Middelheimlaan 1
2020 Antwerpen
Tel. 032653011
Vincent.Pruniau@uantwerpen.be